Advertisement
Screener

INCYTE CORPORATION (INCY) Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets

2.8 / 5 stars · 66/118 Roast Me

INCYTE CORPORATION Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets

INCYTE CORPORATION (INCY) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets of 4.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets · last filed 2026-02-10

  • INCYTE CORPORATION defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2025 was 4.30%, a 21.82% decline from fiscal 2024.
  • INCYTE CORPORATION defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2024 was 5.50%, a 5.17% decline from fiscal 2023.
  • INCYTE CORPORATION defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2023 was 5.80%, a 28.89% increase from fiscal 2022.
  • INCYTE CORPORATION defined benefit plan, assumptions used calculating net periodic benefit cost, expected long-term rate of return on plan assets for fiscal 2022 was 4.50%, a 4400.00% increase from fiscal 2021.
Period endDefined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets 12 month
2025-12-314.30%
10-K · filed 2026-02-10
2024-12-315.50%
10-K · filed 2026-02-10
2023-12-315.80%
10-K · filed 2025-02-10
2022-12-314.50%
10-K · filed 2024-02-13
2021-12-310.10%
10-K · filed 2023-02-07
2020-12-310.30%
10-K · filed 2022-02-08
2019-12-310.75%
10-K · filed 2021-02-09
2018-12-310.75%
10-K · filed 2020-02-13
2017-12-310.75%
10-K · filed 2019-02-14
2016-12-310.75%
10-K · filed 2018-02-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
IQVIA HOLDINGS INC. (IQV)United States$45.926B20.54
Absci Corp (ABSI)United States$1.775B-14.92
OmniAb, Inc. (OABI)United States$0.698B-8.05
NRC HEALTH (NRC)United States$0.450B42.50
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B